Portal de Periódicos da CAPES

Treatment of alopecia areata partim universalis with efalizumab

2006; Elsevier BV; Volume: 55; Issue: 3 Linguagem: Inglês

10.1016/j.jaad.2006.05.062

1097-6787

Ursula Kaelin, Akmhal Said Hassan, L. R. Braathen, N. Yawalkar,

Dermatologic Treatments and Research

Alopecia areata (AA) is considered an autoimmune disease targeted at hair follicles with T-lymphocytes playing an important role in the pathogenesis. Treatment of AA, particularly the totalis and universalis subtypes, is often difficult and remains a therapeutic challenge. Novel biologic therapies that have been developed for the treatment of other immune-mediated inflammatory skin diseases may represent a new therapeutic modality for this disease. Efalizumab is a humanized monoclonal anti-CD11a antibody that inhibits T-cell activation and migration. We report a case of a 19-year-old man suffering from AA partim universalis, treated with efalizumab monotherapy. The treatment was well tolerated with no reported side effects. The striking improvement warrants further studies with this biologic therapy in AA. Alopecia areata (AA) is considered an autoimmune disease targeted at hair follicles with T-lymphocytes playing an important role in the pathogenesis. Treatment of AA, particularly the totalis and universalis subtypes, is often difficult and remains a therapeutic challenge. Novel biologic therapies that have been developed for the treatment of other immune-mediated inflammatory skin diseases may represent a new therapeutic modality for this disease. Efalizumab is a humanized monoclonal anti-CD11a antibody that inhibits T-cell activation and migration. We report a case of a 19-year-old man suffering from AA partim universalis, treated with efalizumab monotherapy. The treatment was well tolerated with no reported side effects. The striking improvement warrants further studies with this biologic therapy in AA. Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006;55:529-32 (September).Journal of the American Academy of DermatologyVol. 55Issue 6PreviewIn the article above, the first names of Drs Hassan, Braathen, and Yawalkar were misspelled. The correct spellings of these names are Akmal Saad Hassan, MD, Lasse Roger Braathen, MD, PhD, and Nikhil Yawalkar, MD. We apologize to the authors for the error. Full-Text PDF